Medicine

Andrew Bateman

MB BS, MRCP, FRCR, PhD

Primary position:
Senior Lecturer
Other positions:
Consultant Clinical Oncologist

Background

The University of Southampton

Dr Andrew Bateman was appointed Senior Lecturer, Cancer Sciences, University of Southampton in 2002 and was recipient of a Cancer Research UK Clinician Scientist award. He had graduated from St Bartholomew’s Hospital Medical School in 1989 and undertaken general medical training in London and the South East. He was appointed to a Clinical Oncology Registrar Training post at the Hammersmith Hospital in 1993, spent a year (’95-’96) in Christchurch, New Zealand, completing the FRCR in ’97. He then entered research as an ICRF clinical research fellow in the laboratory of Dr Richard Vile, initially at the Hammersmith and then subsequently in the Molecular Medicine Program, Mayo Clinic, Rochester, Minnesota.

In 2001-2 Dr Bateman completed his Clinical Oncology training at Mount Vernon Hospital, before obtaining a CR UK Clinician Scientist Fellowship and moving to Southampton. Here he has developed a clinical practice in gastrointestinal malignancy, a focus in clinical trials, and research in cancer immunology and immunotherapy. 

Qualifications

MB BS, University of London (1989)
MRCP, Royal College of Physicians (1992)
FRCR, Royal College of Radiologists (1997)
PhD, Open University (2002)

Appointments held

Clinical Research Fellow, Imperial Cancer Research Fund, 1997-98

Research Associate, Molecular Medicine Program, Mayo Clinic 1998-2001

Clinical Oncology Senior Registrar, Mount Vernon Hospital, 2001 – 2002

Senior Lecturer, Consultant Clinical Oncologist, University of Southampton 2002 - present

Dr Andrew Bateman's photo

Publications

The University of Southampton's electronic library (e-prints)

Article

Noble, Fergus, Nolan, Luke, Bateman, Adrian C., Byrne, James, Kelly, Jamie, Bailey, Ian, Sharland, Donna, Rees, Charlotte, Iveson, T., Underwood, T.J. and Bateman, Andrew R. (2013) Refining pathological evaluation of neoadjuvant therapy for adenocarcinoma of the esophagus. World Journal of Gastroenterology, 19, (48), 9282-9293. (doi:10.3748/wjg.v19.i48.9282).
Williams, Sarah, Bateman, Andrew and O'Kelly, Ita (2013) Altered expression of two-pore domain potassium (K2P) channels in cancer. PLoS ONE, 8, (10), 1-11. (doi:10.1371/journal.pone.0074589).
Noble, Fergus, Hopkins, James, Curtis, Nathan, Kelly, Jamie, Bailey, Ian, Byrne, James, Bateman, Adrian C., Bateman, Andrew R. and Underwood, T.J. (2013) The role of systemic inflammatory and nutritional blood-borne markers in predicting response to neoadjuvant chemotherapy and survival in oesophagogastric cancer. Medical Oncology, 30, (3), 596-609. (doi:10.1007/s12032-013-0596-6). (PMID:23690267).
Chinnery, Fay, King, Catherine A, Elliott, Tim, Bateman, Andrew R and James, Edward (2012) Viral antigen mediated NKp46 activation of NK cells results in tumor rejection via NK-DC crosstalk. Oncolmmunology , 1, (6), 874-883. (doi:10.4161/onci.20636). (PMID:23162755).
Nolan, L., Eccles, D., Cross, E., Crawford, G., Beck, N., Bateman, A. and Ottensmeier, C. (2009) First case report of Muir-Torre syndrome associated with non-small cell lung cancer. Familial Cancer, 8, (4), 359-362. (doi:10.1007/s10689-009-9247-7).
Bateman, Adrian C., Jaynes, Eleanor and Bateman, Andrew R. (2009) Rectal cancer staging post neoadjuvant therapy - how should the changes be assessed? Histopathology, 54, (6), 713-721. (doi:10.1111/j.1365-2559.2009.03292.x).
Nicolas, Alexandra, Cathelin, Dominique, Larmonier, Nicolas, Fraszczak, Jennifer, Puig, Pierre-Emmanuel, Bouchot, André, Bateman, Andrew, Solary, Eric and Bonnotte, Bernard (2007) Dendritic cells trigger tumor cell death by a nitric oxide-dependent mechanism. Journal of Immunology, 179, (2), 812-818.
Williams, Anthony P., Bateman, Andrew R. and Khakoo, Salim I. (2005) Hanging in the balance: KIR and their role in disease. Molecular Interventions, 5, (4), 226-240. (doi:10.1124/mi.5.4.6).
Phan, Vy, Errington, Fiona, Cheong, S. Chiat, Kottke, Tim, Gough, Michael, Altmann, Sharon, Brandenburger, Annick, Emery, Steve, Strome, Scott, Bateman, Andrew, Bonnotte, Bernard, Melcher, Alan and Vile, Richard (2003) A new genetic method to generate and isolate small, short-lived but highly potent dendritic cell-tumor cell hybrid vaccines. Nature Medicine, 9, (9), 1215-1219. (doi:10.1038/nm923).
Ahmed, A., Jevremovic, D., Suzuki, K., Kottke, T., Thompson, J., Emery, S., Harrington, K., Bateman, A. and Vile, R. (2003) Intratumoral expression of a fusogenic membrane glycoprotein enhances the efficacy of replicating adenovirus therapy. Gene therapy, 10, (19), 1663-1671. (doi:10.1038/sj.gt.3302064).
Bateman, Andrew R., Harrington, Kevin J., Kottke, Tim, Ahmed, Atique, Melcher, Alan A., Gough, Michael J., Linardakis, Emmanouela, Riddle, David, Dietz, Allan, Lohse, Christine M., Strome, Scott, Peterson, Tim, Simari, Robert and Vile, Richard G. (2002) Viral fusogenic membrane glycoproteins kill solid tumor cells by nonapoptotic mechanisms that promote cross presentation of tumor antigens by dendritic cells. Cancer Research, 62, (22), 6566-6578.
Linardakis, Emmanouela, Bateman, Andrew, Phan, Vy, Ahmed, Atique, Gough, Michael, Olivier, Keneth, Kennedy, Rick, Errington, Fiona, Harrington, Kevin J., Melcher, Alan and Vile, Richard (2002) Enhancing the efficacy of a weak allogeneic melanoma vaccine by viral fusogenic membrane glycoprotein-mediated tumor cell-tumor cell fusion. Cancer Research, 62, (19), 5495-5504.
Harrington, Kevin J., Bateman, Andrew R., Melcher, Alan A., Ahmed, Atique and Vile, Richard G. (2002) Cancer gene therapy: part 1. Vector development and regulation of gene expression. Clinical Oncology, 14, (1), 3-16. (doi:10.1053/clon.2001.0002).
Harrington, Kevin J., Melcher, Alan A., Bateman, Andrew R., Ahmed, Atique and Vile, Richard G. (2002) Cancer gene therapy: part 2. Candidate transgenes and their clinical development. Clinical Oncology, 14, (2), 148-169. (doi:10.1053/clon.2001.0004).
Kirkham, Lucy A., Bateman, Andrew R., Melcher, Alan A., Vile, Richard G. and Fielding, Adele K. (2002) Lack of specificity of cell-surface protease targeting of a cytotoxic hyperfusogenic gibbon ape leukaemia virus envelope glycoprotein. The Journal of Gene Medicine, 4, (6), 592-600. (doi:10.1002/jgm.306).
 

Research

Research Interests

Dr Andrew Bateman’s research is focused on understanding the tumour micro-environment, assessing potential predictive markers of response to conventional cancer treatments, as well as introducing novel therapies in to the clinic. These projects are conducted with relevance to gastro-intestinal cancers.

Oesophageal cancer

Adenocarcinoma of the oesophagus and oesophago-gastric junction has become the predominant histological tumour type seen in the UK. The majority of cases are thought to evolve through a process of metaplasia (Barrett’s), dysplasia and on to cancer. In conjunction with surgical and pathology colleagues we have built up a database of over 200 patients with matched clinical and pathology covering this spectrum of change in the lower oesophagus. This database is currently being interrogated. The work aims to identify potential drivers of malignant development, neo-antigen expression, predictors of response to neo-adjuvant therapy as well as assessment of the tumour micro-environment with particular focus on the immune environment. A longterm aim will be to design rational immunotherapy strategies for adjuvant treatment of oesophago-gastric cancer.

Immunotherapy trials

In collaboration with Professor Ottensmeier, Dr Bateman has recently obtained Cancer Research UK funding to conduct a Phase 2 DNA vaccine trial in advanced colorectal cancer: The Acacia Trial. This will be a randomized, multi-centre trial which will address the effectiveness of vaccination in this group, the interaction between vaccine and chemotherapy, and the advantage of a dual antigen vaccine strategy.

Clinical Research

Dr Bateman is Clinical Lead of the Central South Coast Cancer Research Network (CSCCRN). The CSCCRN recruits large numbers of patients in to NIHR Trials across a broad range of cancer specific sub groups. Dr Bateman is also active in the radiation subgroup of the Upper GI site specific group and is involved in developing a Phase 2 study of neo-adjuvant chemoradiotherapy in oesophageal cancer.

Academic unit:  Cancer Sciences

Research project

Effect of folic acid supplementation during the life course on cancer susceptibility

Responsibilities

Postgraduate student supervision

Mr Fergus Noble, FRCS
Ms Sarah Williams

Faculty of Medicine

Admissions selector

National responsibilities

FRCR Part 1 examiner 2005 - present

Contact

Dr Andrew Bateman
Faculty of Medicine
University of Southampton
Southampton General Hospital
Mailpoint 801
South Academic Block
Tremona Road
Southampton
SO16 6YD
or
Faculty of Medicine
University of Southampton
Building 85
Life Sciences Building
Highfield Campus
Southampton
SO171BJ

Room Number: SGH/MP824